Clinical Trial Update: A Phase I/II Study to Assess the Safety and Tolerability of APO866 for the Treatment of Refractory B-CLL [Phase 1, Phase 2]

View source ↗

Summary

A Phase I/II trial evaluating the safety and tolerability of APO866 in patients with refractory B-cell chronic lymphocytic leukemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• APO866

Snippet

Sponsor: Valerio Therapeutics | Conditions: B-cell Chronic Lymphocytic Leukemia | Phase 1, Phase 2 | Status: COMPLETED